Purpose: The effect of delays in surgical treatment on survival outcomes in patients with breast cancer remains uncertain, but it is an issue of importance to both patients and clinicians. The purpose of this study was to determine the impact of delayed surgical treatment on survival and tumor progression such as changes in tumor size and lymph node metastasis. Methods: Among 1,219 patients who underwent breast cancer surgery at Asan Medical Center between January 2008 and December 2008, 1,074 patients were finally included in the study following the application of inclusion and exclusion criteria. Patients were divided into two groups based on the interval between diagnosis and surgery: ≤ 30 days (group 1) and > 30 days (group 2). We retrospectively analyzed clinical characteristics, changes in tumor size and axillary lymph-node status, and overall survival (OS) and disease-free survival (DFS) rates. Results: Between group 1 and group 2, there were no differences in clinical characteristics or in changes in tumor size between findings based on ultrasonography (USG) with biopsy at diagnosis and pathologic results (p= 0.134). Furthermore, changes in tumor size and lymph-node status between USG results at Asan Medical Center and pathologic results also showed no differences (p= 0.249 and p= 0.233, respectively). There were also no significant differences in DFS (p= 0.395) or OS (p= 0.813). Conclusion: Our study showed that short-term delays of ≤ 2 months between diagnosis and surgery for breast cancer do not negatively affect cancer progression or survival rates.
INTRODUCTION
Breast cancer is one of the most common female cancers throughout the world and the number of newly diagnosed patients is increasing worldwide [1] . The initiation of appropriate treatment is often delayed owing to a variety of patient, provider, and health system factors.
Often, treatment delay following a diagnosis of breast cancer causes patients significant psychological and social distress. In recent retrospective studies conducted in Korea, based on data from the Korean Central Cancer Registry (KCCR), the median time from breast cancer diagnosis to surgery was 14 days, and the proportion of patients with breast cancer who had undergone surgery within 4 weeks of the diagnosis of cancer was 74.1% [2] . In the United States, a study based on the Surveillance, Epidemiology, and End Results Program (a database maintained by the National Cancer Institute) found that the median interval (delay) between first physician visit and surgery between 1992 and 2005 was 29 days, with an increase from 21 days in 1992 to 32 days in 2005 [3] .
The influence of surgical treatment delay on the survival rate is still uncertain, and the acceptable time interval from the diagnosis of breast cancer to surgery remains controversial. In Korea, two retrospective studies demonstrated a negative impact of delayed surgical treatment on survival outcomes. In the first study, patients with surgery delayed for more than 30 days showed worse survival rates compared to those who underwent surgery within 30 days after the initial cancer diagnosis (adjusted hazard ratio [aHR], 1.59; 95% confidence interval [CI], 1.37-1.84) [2] . Similarly, in the second study, patients with surgery delayedwfor more than 12 weeks showed worse survival rates compared to those who underwent surgery within 12 weeks following diagnosis (aHR, 1.91; 95% CI, 1.06-3.49) [4] . These two studies, however, included limited detailed information on individual patient clinical characteristics in that patient data were derived from the government's information database from the KCCR or from the Korea National Statistical Office database. Similarly, in the United States, a recent retrospective study on young patients with breast cancer, aged 15 to 39 years, reported a similar outcome: the 5-year survival rate in women 101 who were treated with surgery and had a treatment delay of > 6 weeks was only 80% compared with a rate of 90% among those with a treatment delay of < 2 weeks (p = 0.005) [5] . On the other hand, several other studies have suggested that surgical treatment delay had no significant impact on patient survival outcomes [6] [7] [8] [9] . In Korea, Yoo et al. [6] showed that a delay of treatment initiation with cutoff values of 15, 30, 45, and 60 days had no impact on disease-free survival (DFS) or overall survival (OS) in breast cancer (DFS, p = 0.079, p = 0.101, p = 0.431, and p = 0.839, respectively). In the United States, Brazda et al. [7] reported that two hospitals (Parkland Memorial Hospital and Simmons Comprehensive Cancer Center) showed different time delays of 53.4 ± 2.0 days and 33.2± 1.2 days, respectively, between the diagnosis of breast cancer and surgery. The authors then compared the OS of the patients, dividing their time delay into 0-45 days, 46-90 days, and >90 days, but found no significant differences [7] . Moreover, in the United States, Eastman et al. [8] analyzed the influence of delay from diagnosis until surgery on OS and locoregional recurrence (LRR) in 301 patients with triple-negative breast cancer. They determined that the mean interval to treatment was 46 ± 2 days, and the interval did not affect OS (p = 0.24). The authors also found that LRR was observed in 20 patients (7%), time to treatment was 38± 6 days, and delayed surgical treatment did not have an influence on LRR (p = 0.54) [8] . Mujar et al. [9] in Malaysia analyzed how a delayed time to surgery of 30 days affected OS in 648 patients with breast cancer who underwent surgery at Malaya University Medical Center. They found no significant differences in univariate or multivariate analyses.
Because of the currently available data on treatment, studies on time delays are limited and retrospective, and the results are debatable considering the acceptable wait time and whether there is any correlation with effects on tumor progression and survival outcomes. Presently, with increasing numbers of patients with breast cancer undergoing surgery, the issue of how great a period of wait time between diagnosis and surgical treatment is acceptable has become a key point of debate for both patients and clinicians. Thus, in the current study, we examined whether short-term delays influence cancer progression and survival rates.
Unlike other studies, the present study featured an analysis based on a comparatively well-structured large-volume database from a single organization and attempted to overcome the limitations of previous studies through the utilization of results obtained from a single hospital in which diagnosis, operation, and pathological analysis has been conducted consistently. Furthermore, the present study did not only include research limited to surgical outcomes, as in many past studies, but also provided further analyses of tumor progression such as tumor growth and lymph node metastasis. Based on our database, the objectives of the current study were (1) to determine the impact of the delay from cancer diagnosis to surgery on survival, and (2) to determine the correlation between the prolongation of these delays and tumor progression such as tumor growth and lymph node metastasis. We analyzed changes in tumor size between USG findings at initial diagnosis and pathological results after surgery, as well as changes in tumor size and lymph node status between USG performed at Asan Medical Center and pathological results after surgery in both group 1 and group 2. Proportional variables were compared between the two groups using the chi-square test. Survival curves were generated using the Kaplan-Meier method, and the significance of survival differences among selected variables was verified using the log-rank test. The cutoff for statistical significance was set at p < 0.05. All statistical analyses were performed using SPSS version 21.0 (IBM Corp., Armonk, USA). According to these results, when comparing disease progression in patients whose operation was delayed for more than 30 days after diagnosis with that in those whose operation was performed within 30 days after diagnosis, there were no important distinctions between 
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the two groups in terms of tumor size change or lymph node metastasis (Table 3) .
During the median follow-up period (71 months for group 1 and 72 months for group 2), no significant statistical difference was found be- Two previous studies were conducted in South Korea. In the first study, patients who experienced surgical delays of more than 30 days showed worse survival rates compared to those who underwent surgery within 30 days after the initial diagnosis [2] . Similarly, in the sec- 
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ond study, patients who underwent delayed surgery (after more than 12 weeks) showed worse survival rates compared to those who underwent surgery within 12 weeks after the initial diagnosis [4] .
Similarly, in the United States, a recent retrospective study on young patients with breast cancer, aged 15 to 39 years, reported that the 5-year survival rate worsened when the delay in treatment time was over 6 weeks [5] . However, because the above-mentioned studies were performed based on patient information from government databases, it might be necessary to review the accuracy of the databases and results. These studies included no analyses of the clinical characteristics of patient groups and, furthermore, they were heterogeneous in diagnostic methods and operational methods. Thus, there might be biases in judging the effects of surgical treatment delays on prognoses. In contrast to previous studies, the present study analyzed a database of patients with breast cancer surgery executed solely at our hospital. The current study separated the time of delay from diagnosis until surgery into periods of >30 days and ≤ 30 days, and compared the two groups; the results of this analysis showed that the prognosis of patients whose time delay was >30 days was not significantly different from that of those whose time delay was ≤ 30 days. Also unlike previous studies, to achieve greater reliability, the present study conducted analyses based on a large-volume database from a single institution, and evaluated diagnostic and surgical methods as well as pathological analyses performed within our own well-developed oncology hospital. Furthermore, this study was able to increase the accuracy of diagnoses prior to surgery by allowing only specialized radiologists for breast cancer to perform USG on all patients before surgery.
It also limited the surgical method to two types: BCS or mastectomy, and included only stage I to III patients to limit biases affecting results.
Lastly, it heightened the reliability of results in that pathological results were also obtained within this single institution. Moreover, the pres- tion. In terms of DFS or OS rates, it was revealed that prognoses between the two groups were similar, owing to the observation of no significant differences between the two groups. Among data in the present study, with the exception of case 11, in which the waiting period was longer than 60 days, no significant differences were found between the two groups. In a study that compared delay times from initial diagnosis until surgery on the shorter basis of ≤15 days or >15 days, the gap between the two groups was found to be even further decreased. In that study, DFS and OS rates were also compared between group 1 and group 2 for patient age (age < 35 years or ≥ 35 years), histologic grade (HG 1-2, HG 3), tumor stages (I, II, and III), and each tumor subtype. However, these data similarly showed no significant differences (data not shown).
As shown in Table 1 , surgical method, postoperative chemotherapy, and radiotherapy demonstrated significant differences between the two groups. Group 2 had a higher proportion of patients who underwent mastectomy, and most of these patients received reconstructive surgery at the same time (group 1, 17.3% vs. group 2, 60.5%). These immediate reconstructive surgeries following mastectomy sometimes led to scheduling problems, which may also lengthen the waiting time for surgery. Because the proportion of patients who underwent BCS in group 1 was greater than that in group 2, postoperative radiotherapy was more often performed in group 1 (74.0% vs 58.1%, p < 0.001).
Postoperative chemotherapy was also more often performed in group 1 (68.0% vs. 58.1%, p = 0.012). While the findings are difficult to explain, the proportions of ER-negative, PR-negative, triple-negative subtype, histologic grade 3, and pathologic tumor size (2-5 cm) were all higher in group 1. It is hypothesized that these chemotherapy-relat-Jonguk Lee, et al.
ed factors could be associated with the higher proportions of postoperative chemotherapy in group 1.
The U.K. government introduced the "Cancer waiting time targets" in the year 2000 and recommended that the overall time from referral of the patient with suspected cancer to diagnosis and the initiation of treatment should not exceed 62 days. However, the association between these waiting time targets and prognosis might differ according to cancer type [11, 12] .
Certainly, a multidisciplinary approach is recommended for effective breast cancer treatment, and if patients would be able to receive sufficient time for evaluation regarding appropriate curative surgery, they could receive more positive treatment effects, even though this might require longer waiting times (up to 2 months) from diagnosis until surgery. This outcome of being able to wait longer without adverse effects could be helpful in reducing the severe anxiety experienced by some patients who might suffer from worry regarding prolonging the initiation of surgical processes after having received diagnoses of breast cancer.
This study does have some limitations. First, this survey was retrospectively performed at a single institution, and it was not a multicenter study. Because of differences in each institution's preoperative evaluation policy, there is risk in generalizing the results of this study.
In 2008, when the patients in this study were evaluated, routine preoperative evaluations for breast cancer patients in Asan Medical Center were mammography and USG, and more complex examinations such as computed tomography, magnetic resonance imaging, or positron emission tomography were not routinely performed. Secondly,
the present study did not analyze the effect caused by surgical treatment delays of more than 60 days, because there were only 11 such cases. Thirdly, because we retrospectively collected each patient's clinical data, we might be unable to control bias regarding clinical results.
Fourthly, we compared the preoperative tumor size based on USG with the postoperative pathologic size to compare postsurgical changes in tumor size owing to surgical delay. We agree that this method is not objective and there may be discrepancies in the tumor size because of changes in the method of measurement. Because we did not perform additional USG before surgery, comparison of the tumor size with USG was not possible. In addition, as we did not routinely perform axillary lymph node biopsy (fine-needle aspiration or core needle biopsy) in all patients, we had to compare the node status with clinical USG findings and pathologic findings for this report. To strengthen its contentions, findings, and implications for future patients with breast cancer, the results of the present study need to be compared to the results of previous studies and also further investigated through a long-term follow-up study involving a large number of patients to validate these data and findings.
In conclusion, the present study found that among patients divided into two groups consisting of those undergoing surgery before 30 days and after 30 days from diagnosis of invasive breast cancer to surgery, comparison of data revealed no important differences in change of tumor size or change of metastatic lymph node status between the two groups. Furthermore, no significant gap for either DFS or OS rate was found between the two groups. Consequently, the results from this study have shown that during a comparatively short period of 2 months after the diagnosis of breast cancer, such delays in surgery did not adversely affect cancer progression and respective survival rates.
Nonetheless, this argument still needs to be proven through a larger-scale, long-term study based on a larger patient sample size in the future.
